Life Science Investing MiNK Therapeutics and University of Wisconsin-Madison Announce Phase 1 Clinical Trial of Allo-iNKT Cell Therapy to Evaluate Prevention of Graft-Versus-Host Disease
Life Science Investing MiNK Therapeutics to Report Third Quarter 2025 Financial Results and Highlight Clinical and Corporate Milestones Advancing iNKT Platform Toward Pivotal Development
Life Science Investing MiNK Therapeutics to Present Late-Breaking Data on AgenT-797 in Solid Tumors at the 40th Annual Society for Immunotherapy of Cancer Meeting
Life Science Investing MiNK Therapeutics Dr. Jennifer Buell to Deliver Featured Plenary at 10th Annual CAR-TCR Summit in Boston, MA
Life Science Investing MiNK Therapeutics Appoints Dr. Terese C. Hammond to Accelerate iNKT Pipeline to Pivotal Development
RZOLV Technologies Announces Independent SGS Lab-Scale Test Results on Gravity Concentrates - 98.7% Gold Recoveries
